PDF

Fortress Biotech, Inc. Class Action Lawsuit

6 days left to seek lead plaintiff status

Case Summary

Company Name
Fortress Biotech, Inc.
Stock Symbol
FBIO
Class Period
December 11, 2019 to October 9, 2020
Motion Deadline
January 26, 2021
Court
Eastern District of New York

The Fortress Biotech, Inc. class action lawsuit charges Fortress Biotech and certain of its executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers or acquirers of Fortress Biotech securities between December 11, 2019 and October 9, 2020, inclusive (the “Class Period”).  The Fortress Biotech class action lawsuit was commenced on November 27, 2020 in the Eastern District of New York and is captioned Cushman v. Fortress Biotech, Inc., No. 20-cv-05767.

Fortress Biotech develops and commercializes pharmaceutical and biotechnology products.  In December 2019, Fortress Biotech’s majority-controlled subsidiary, Avenue Therapeutics, Inc., which Fortress Biotech founded in 2015, submitted a New Drug Application (“NDA”) for its intravenous (“IV”) Tramadol product to the U.S. Food and Drug Administration (“FDA”) for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

The Fortress Biotech class action lawsuit alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) IV Tramadol was not safe for the intended patient population; (ii) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (iii) as a result, Fortress Biotech’s public statements were materially false and misleading at all relevant times.

On October 12, 2020, Avenue Therapeutics disclosed receipt of a Complete Response Letter (“CRL”) from the FDA regarding the NDA for its IV Tramadol product.  Specifically, the FDA advised Avenue Therapeutics that “it cannot approve the application in its present form” because “IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population.”  Specifically, the CRL stated: “[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed.  The likely choice would be another opioid, which would result in opioid ‘stacking’ and increase the likelihood of opioid-related adverse effects.”  On this news, Fortress Biotech’s stock price fell nearly 24%, damaging investors.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Fortress Biotech securities during the Class Period to seek appointment as lead plaintiff in the Fortress Biotech class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Fortress Biotech class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Fortress Biotech class action lawsuit.  An investor’s ability to share in any potential future recovery of the Fortress Biotech class action lawsuit is not dependent upon serving as lead plaintiff.  If you wish to serve as lead plaintiff of the Fortress Biotech class action lawsuit or have questions concerning your rights regarding the Fortress Biotech class action lawsuit, please provide your information here or contact counsel, Michael Albert of Robbins Geller, at 800/449-4900 or 619/231-1058 or via e-mail at malbert@rgrdlaw.com.  Lead plaintiff motions for the Fortress Biotech class action lawsuit must be filed with the court no later than January 26, 2021.

Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities class action litigation.  With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history.  For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements.  Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims.  Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide.  Robbins Geller attorneys are consistently recognized by courts, professional organizations and the media as leading lawyers in the industry.

Class Period: December 11, 2019 - October 9, 2020
Main Menu